What type of study is this?

This is a Literature Review study.

October 11, 2025Open Access

Therapeutic strategies targeting ocular vasculopathies: Current advances and emerging challenges

Key Points

Anti-VEGF therapies significantly improved outcomes in ocular vasculopathies but face challenges including variable response and resistance.
Emerging strategies involve targeting pathways like PDGF and Ang-2 to enhance treatment efficacy and overcome established limitations.
Innovations such as gene therapy and long-acting biologics are promising for sustained treatment while reducing frequent injections.
Exploring complementary approaches targeting inflammation and neuroprotection may help preserve retinal function and optimize therapy.

Abstract

Ocular vasculopathies, including neovascular age-related macular degeneration (wet AMD), diabetic retinopathy, retinal vein occlusion, and radiation maculopathy, are major causes of vision loss driven by vascular endothelial growth factor (VEGF)-mediated neovascularization. Anti-VEGF therapies have transformed outcomes but face limitations from resistance, variable response, frequent injections, and adverse effects of broad VEGF blockade. This review discusses emerging approaches, including platelet-derived growth factor (PDGF), angiopoietin-2 (Ang-2), tyrosine kinase with immunoglobulin-like and EGF-like domains 2 (Tie2), and integrin inhibitors, alongside innovations in long-acting biologics, gene therapy, and nanocarriers. Complementary strategies targeting alternative angiogenic pathways, inflammation, hypoxia, and neuroprotection might overcome resistance and preserve retinal function. Together, these advances highlight opportunities to optimize therapy and address unmet needs in ocular vasculopathies.

Therapeutic strategies targeting ocular vasculopathies: Current advances and emerging challenges

Key Points

Abstract

Cite This Study

Also Consider

Also Consider